Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Rusfertide · 2 trials · 1 indication
Response is defined as the absence of phlebotomy eligibility. Phlebotomy eligibility is defined as: A confirmed hematocrit ≥45%, which is ≥3% (absolute) higher than the baseline hematocrit or hematocrit ≥48%. Confirmation is defined as 2 consecutive hematocrit assessments that are ≥45% and at least 3% higher than the baseline hematocrit.
| Arm | Type | Description |
|---|---|---|
| Rusfertide | EXPERIMENTAL | Participants will receive rusfertide (TAK-121), subcutaneously (SC) once weekly for 52 weeks. |
| Name | Type | Description |
|---|---|---|
| Rusfertide | DRUG | Rusfertide injections administered SC. |
* Inclusion Criteria 1. Chinese male and female participants aged 18 years or older at the time of signing of informed consent. 2. Participant understands the trial procedures, is willing and able to adhere to trial requirements, and agrees to participate in the trial by providing written infor...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Protagonist Therapeutics, Inc. | PTGX | 2 | PHASE3 | Rusfertide |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-3405 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Novartis AG Sponsored ADR | NVS | 1 | - | Undisclosed |
Rusfertide is an investigational small molecule being studied for the treatment of polycythemia vera, a blood disorder characterized by an overproduction of red blood cells. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Rusfertide is a peptide-based therapeutic, as indicated by its '-tide' suffix. It is being developed to address polycythemia vera, though its specific molecular target has not been disclosed in available clinical trial information.
Rusfertide is being developed by Takeda Pharmaceutical Company Limited, a global biopharmaceutical company listed on the stock exchange under the ticker TAK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with polycythemia vera.
Rusfertide is currently in Phase 2 clinical development. Two Phase 2 trials are ongoing or planned, one recruiting in Japan and another not yet recruiting in China, both focused on adults with polycythemia vera. The drug is investigational and not yet approved.
Rusfertide is being studied in two Phase 2 trials. NCT07648030 is a study in Japanese adults with polycythemia vera, currently recruiting with an enrollment target of 9 participants. NCT07765602 is a study in adults with polycythemia vera in China, not yet recruiting, with an enrollment target of 24 participants.
Rusfertide is a distinct investigational drug developed by Takeda. No alternative names for Rusfertide have been reported in the context of its clinical development for polycythemia vera.